NASDAQ : CLGN
CollPlant Biotechnologies Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 4.135 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.82M |
| Enterprise Value | 7.92M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 25, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.89M |
| Shares Outstanding | 1.89M |
| Shares Change (YoY) | +16.22% |
| Shares Change (QoQ) | +4.94% |
| Owned by Insiders (%) | 40.14% |
| Owned by Institutions (%) | 8.76% |
| Float | 1.13M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.59 |
| Forward PS | 7.52 |
| PB Ratio | 2.03 |
| P/TBV Ratio | 2.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 24.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.57 |
| Quick Ratio | 1.19 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -165.40 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -161.98% |
| Return on Assets (ROA) | -62.95% |
| Return on Invested Capital (ROIC) | -73.36% |
| Return on Capital Employed (ROCE) | -263.32% |
| Weighted Average Cost of Capital (WACC) | 6.86% |
| Revenue Per Employee | $8,154 |
| Profits Per Employee | -$320,846 |
| Employee Count | 39 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 2.45 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -81.20% |
| 50-Day Moving Average | 3.69 |
| 200-Day Moving Average | 5.11 |
| Relative Strength Index (RSI) | 56.22 |
| Average Volume (20 Days) | 50,499 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 52,732 |
| Short Previous Month | 42,221 |
| Short % of Shares Out | 2.12% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.74 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 318,000 |
| Gross Profit | -1.02M |
| Operating Income | -12.41M |
| Pretax Income | -12.51M |
| Net Income | -12.51M |
| EBITDA | -11.56M |
| EBIT | -12.41M |
| Loss Per Share | -$9.32 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.56M |
| Total Debt | 2.66M |
| Net Cash | -101,000 |
| Net Cash Per Share | -$0.05 |
| Equity (Book Value) | 2.95M |
| Book Value Per Share | 2.04 |
| Working Capital | 1.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -11.19M |
| Capital Expenditures | -91,000 |
| Depreciation & Amortization | 846,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.29M |
| FCF Per Share | -$5.97 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -3,900.94% |
| Pretax Margin | -3,934.91% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.22% |
| Shareholder Yield | -16.22% |
| Earnings Yield | -225.42% |
| FCF Yield | -144.34% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 7.45% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 4, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -28.14 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |